| abstract |
The invention relates to an aqueous ophthalmic pharmaceutical composition comprising: a) at least 0.4% w / v of bilastine, of the formula or a pharmaceutically acceptable salt or solvate thereof, in which the bilastine, salt or solvate it is completely dissolved in the pharmaceutical composition; b) at least one α-cyclodextrin; and c) at least one pharmaceutically acceptable water soluble gelling agent; and in which the pH is between 4 and 9. |